Finland's Orion Q3 sales rise 28%; upgrades 2026 outlook
Finland's Orion Q3 sales rise 28%; upgrades 2026 outlook
Overview
Finland pharma firm's Q3 net sales rose 28% yr/yr
Q3 basic EPS increased 74% yr/yr
Company upgraded 2026 outlook for net sales and operating profit
Outlook
Orion sees 2026 net sales at EUR 2,070 mln to EUR 2,140 mln
Company expects 2026 operating profit of EUR 730 mln to EUR 790 mln
Orion raised 2026 outlook citing strong growth in Nubeqa royalties
Result Drivers
INNOVATIVE MEDICINES AND BRANDED PRODUCTS - Co said Q3 revenue growth was driven by Innovative Medicines and Branded Products divisions
ROYALTY INCOME - Co said improved profitability was mainly due to increased royalty income
NUBEQA SALES - Co said Nubeqa sales were the main driver of net sales growth
Company press release: ID:nGNE85s0k3
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales |
| EUR 542.20 mln |
|
Q3 Net Income |
| EUR 167.60 mln |
|
Q3 Basic EPS |
| EUR 1.19 |
|
Q3 Operating Profit |
| EUR 209.90 mln |
|
Q3 Pretax Profit |
| EUR 210.20 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Orion Oyj is €87.00, about 9.1% below its October 27 closing price of €95.75
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 17 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)